Treatments – PULMONARY HYPERTENSION

Cereno Scientific reports favorable safety and tolerability after 12 months of CS1 treatment in pulmonary arterial hypertension (PAH)from the Expanded Access Program (EAP), March 31, 2026

Cereno Scientific has reported initial findings from a 12-month Expanded Access Program (EAP) with its oral drug candidate CS1 in pulmonary arterial hypertension (PAH), enrolling ten patients who had completed the previous Phase IIa trial. The results confirm a favourable safety and tolerability profile over long-term use, consistent with earlier findings, with no unexpected safety […]

Cereno Scientific reports favorable safety and tolerability after 12 months of CS1 treatment in pulmonary arterial hypertension (PAH)from the Expanded Access Program (EAP), March 31, 2026 Read Post »

A case report about initial triple combination therapy including sotatercept in a patient with severe idiopathic pulmonary arterial hypertension (IPAH), ERJ Open Research, March 30, 2026

To date sotatercept has only been studied in patients with prevalent pulmonary arterial hypertension receiving stable background therapy, not as part of the initial treatment regimen in newly diagnosed patients. A case report, published recently on the ERJ Open Research, describes a 25-year-old woman who developed severe high-risk idiopathic pulmonary arterial hypertension (IPAH) shortly after

A case report about initial triple combination therapy including sotatercept in a patient with severe idiopathic pulmonary arterial hypertension (IPAH), ERJ Open Research, March 30, 2026 Read Post »

Martine Rothblatt, founder and CEO of United Therapeutics, included in Forbes’ America’s Greatest Innovators list

Martine Aliana Rothblatt (born 1954) is an American lawyer, author, and entrepreneur. She founded United Therapeutics in 1996, to make medicines for her daughter who suffered from pulmonary arterial hypertension, and is now developing genetically modified pig organs for human transplant. On the latter topic she has written a book titled “Your life or mine

Martine Rothblatt, founder and CEO of United Therapeutics, included in Forbes’ America’s Greatest Innovators list Read Post »

Sotatercept in pulmonary arterial hypertension: A step-by-step approach for considering the new kid on the block, CHEST, March 4, 2026

Since sotatercept received Food and Drug Administration (FDA) approval for pulmonary arterial hypertension in March 2024, knowing when and how to use it has become an essential part of managing this serious condition — so say the authors of a recently published article in CHEST, who offer a practical guide for clinicians navigating this new

Sotatercept in pulmonary arterial hypertension: A step-by-step approach for considering the new kid on the block, CHEST, March 4, 2026 Read Post »

A Comprehensive literature review on the pathophysiology, mechanism, diagnosis, and management of pulmonary arterial hypertension, US Cardiology Review, January 28, 2026

This review covers the full clinical picture of pulmonary arterial hypertension (PAH) — from its pathophysiology and diagnosis through to current and emerging treatments. Understanding the Disease Pulmonary arterial hypertension is driven by progressive structural remodelling of the pulmonary arteries, creating a vicious cycle of vasoconstriction, inflammation, and uncontrolled cell growth that ultimately leads to

A Comprehensive literature review on the pathophysiology, mechanism, diagnosis, and management of pulmonary arterial hypertension, US Cardiology Review, January 28, 2026 Read Post »

Treatment paradigm shifts in pulmonary arterial hypertension: evidence from a phase 3 study in Asia on sotatercept, JACC, March 3, 2026

A Japanese study has confirmed that sotatercept works just as well in Asian patients, even though pulmonary arterial hypertension presents somewhat differently in the Asian population: patients tend to have longer disease duration, more severe baseline profiles, and are more frequently on intensive triple therapy including parenteral prostacyclin. This was a regional Phase 3, open-label

Treatment paradigm shifts in pulmonary arterial hypertension: evidence from a phase 3 study in Asia on sotatercept, JACC, March 3, 2026 Read Post »

United Therapeutics announces results for its Phase 3 ADVANCE OUTCOMES study on ralenipag for pulmonary arterial hypertension, March 2, 2026

United Therapeutics has announced promising results from its pivotal Phase 3 ADVANCE OUTCOMES study of ralinepag, a new oral treatment for pulmonary arterial hypertension (PAH). Ralinepag is a highly selective prostacyclin (IP) receptor agonist that works through multiple pathways — vasodilatory, anti-proliferative, and anti-inflammatory. It is taken once daily orally, yet achieves sustained receptor activity

United Therapeutics announces results for its Phase 3 ADVANCE OUTCOMES study on ralenipag for pulmonary arterial hypertension, March 2, 2026 Read Post »

Nippon Shinyaku reports progress on trials on NS-863 targeting pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)

Nippon Shinyaku recently reported progress on two Phase 2 trials of its oral candidate NS-863, targeting pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), both serious cardiopulmonary conditions with high unmet need. By advancing NS-863 across two related indications, the company is signaling a deeper push into rare cardiopulmonary therapeutics,

Nippon Shinyaku reports progress on trials on NS-863 targeting pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) Read Post »

Why Wait for Sick People to Get Sicker? The Paradox of the Treatment of Patients With Pulmonary Arterial Hypertension, Pulmonary Circulation, November 20, 2025

Pulmonary arterial hypertension (PAH) is a progressive, life-threatening disease where early detection is strongly encouraged to prevent irreversible vascular and cardiac damage. However, a fundamental paradox exists: while clinicians are urged to diagnose pulmonary arterial hypertension early, treatment is restricted to symptomatic patients (New York Heart Association (NYHA) functional class II or higher), leaving asymptomatic

Why Wait for Sick People to Get Sicker? The Paradox of the Treatment of Patients With Pulmonary Arterial Hypertension, Pulmonary Circulation, November 20, 2025 Read Post »

Understanding Risk Assessment in Pulmonary Arterial Hypertension, International Society for Heart and Lung Transplant ISHLT Consensus Statement, The Journal of Heart and Lung Transplantation – September 05, 2025

What is pulmonary arterial hypertension and why does risk assessment matter? Pulmonary arterial hypertension is a rare, serious disease where the blood vessels in thelungs become too narrow. This makes the right side of the heart work harder, which overtime can lead to heart failure. Because it can progress quickly, doctors use risk assessment (sometimes

Understanding Risk Assessment in Pulmonary Arterial Hypertension, International Society for Heart and Lung Transplant ISHLT Consensus Statement, The Journal of Heart and Lung Transplantation – September 05, 2025 Read Post »

The Pulmonary Hypertension Global Patient Survey: understanding the experiences and perspectives of patients, European Respiratory Journal Open Research 2025

The key findings from the Pulmonary Hypertension Global Patient Survey (PHGPS) adult cohort of 3,329 patients have been published in the ERJ Open Research 2025, highlighting the achievements, shortcomings & regional disparities of clinical care & research globally. The Pulmonary Hypertension Global Patient Survey represents the most extensive survey of its type in the pulmonary

The Pulmonary Hypertension Global Patient Survey: understanding the experiences and perspectives of patients, European Respiratory Journal Open Research 2025 Read Post »

Societal Costs Associated With Pulmonary Arterial Hypertension Subgroups: A Study Utilizing Linked National Registries, Pulmonary Circulation, April 17, 2025

Pulmonary arterial hypertension (PAH) represents a significant economic burden on society, as revealed by a comprehensive Swedish study published on Pulmonary Circulation on April 17, 2025, examining the societal costs associated with this condition. The research tracked patients across various pulmonary arterial hypertension subgroups—idiopathic/hereditary pulmonary arterial hypertension, pulmonary arterial hypertension associated with connective tissue disease,

Societal Costs Associated With Pulmonary Arterial Hypertension Subgroups: A Study Utilizing Linked National Registries, Pulmonary Circulation, April 17, 2025 Read Post »

Proud to celebrate the 14 live webinars we have organised since the series launched in June 2023! A huge thank you to all our speakers and participants!

The Alliance for Pulmonary Hypertension (AfPH) recently concluded its 14th webinar, marking the culmination of an educational initiative that began in June 2023. These virtual gatherings brought together internationally renowned experts in pulmonary hypertension, who shared their expertise on a comprehensive range of topics crucial to advancing patient care and quality of life. The diverse

Proud to celebrate the 14 live webinars we have organised since the series launched in June 2023! A huge thank you to all our speakers and participants! Read Post »

Prostacyclins Show New Hope for Inoperable CTEPH Patients: Meta-analysis Insights, Marisa Wexler, Pulmonary Hypertension News, November 6, 2024

A recent article on Pulmonary Hypertension News reports on the findings of a meta-analysis which suggest that prostacyclin pathway-targeting therapies hold promise for treating chronic thromboembolic pulmonary hypertension (CTEPH), particularly patients who are ineligible for surgery or experience persistent/recurrent symptoms after surgical intervention. However, the authors emphasize the need for larger-scale studies to confirm the

Prostacyclins Show New Hope for Inoperable CTEPH Patients: Meta-analysis Insights, Marisa Wexler, Pulmonary Hypertension News, November 6, 2024 Read Post »

Vienna Lung Failure and Transplantation Symposium 2025, 26 -27 June, 2025

are excited to announce an upcoming two- day international symposium focused on “Lung Failure and Transplantation”. This symposium, organised by the Department of Thoracic Surgery and the Comprehensive Center for Chest Diseases at MedUni Vienna/University Hospital Vienna, aims to address all treatment aspects of end-stage lung failure, including lung transplantation, within an international interdisciplinary setting,

Vienna Lung Failure and Transplantation Symposium 2025, 26 -27 June, 2025 Read Post »

The UK Pulmonary Hypertension Association Chair, Dr Iain Armstrong, explains what happens next with sotatercept and what will be considered when it comes to making decisions for the UK

The first-in-class pulmonary arterial hypertension drug sotatercept was approved in March 2024 by the Food and Drug Administration (FDA) in the USA and the approval of the European Medicines Agency (EMA) is expected in the next few months. The UK Pulmonary Hypertension Association, PHA UK, has put together a short video, with its Chair Dr

The UK Pulmonary Hypertension Association Chair, Dr Iain Armstrong, explains what happens next with sotatercept and what will be considered when it comes to making decisions for the UK Read Post »

The Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA) has recommended granting a marketing authorisation for Winrevair (sotatercept)

On 28 June 2024 the European Medicines Agency has issued a press release to say that the CHMP (human medicines committee) has recommended granting a marketing authorisation in the European Union (EU) for Winrevair (sotatercept) to treat adult patients with pulmonary arterial hypertension (PAH), in combination with other specific PAH therapies, to improve exercise capacity. This is the first step

The Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA) has recommended granting a marketing authorisation for Winrevair (sotatercept) Read Post »

Full transcripts of the Alliance for Pulmonary Hypertension’s 2023 webinars now available for in a format that can be translated into 40 languages

The full transcripts of the Alliance for Pulmonary Hypertension’s 2023 six webinars are now available! The transcripts encapsulate invaluable insights that continue to resonate with current trends and emerging issues, serving as a vital resource for our community. They are now in a format that can be translated into 40 languages, thanks to the embedded

Full transcripts of the Alliance for Pulmonary Hypertension’s 2023 webinars now available for in a format that can be translated into 40 languages Read Post »

The US Food and Drug Administration, FDA, approves sotatercept, Merck’s new drug for pulmonary arterial hypertension, March 26, 2024

The US Food and Drug Administration has approved sotatercept, Merck‘s new drug for pulmonary arterial hypertension. It’s commercial name is Winrevair. Read more on the FDA website at this link Sotatercept is an activin receptor type IIA-Fc (ActRIIA-Fc) fusion protein. It was evaluated as an add-on to stable background therapy for the treatment of pulmonary

The US Food and Drug Administration, FDA, approves sotatercept, Merck’s new drug for pulmonary arterial hypertension, March 26, 2024 Read Post »

The US Food and Drug Administration, FDA, approves the single tablet combination macitentan/tadalafil for pulmonary arterial hypertension, March 22, 2024

On March 22, 2024 the Food and Drug Administration (FDA), the US drug regulatory authority, approved the single-tablet macitentan/tadalafil combination (Opsynvi) for pulmonary arterial hypertension. The application to the FDA was submitted by the Janssen Pharmaceutical Companies of Johnson & Johnson on May 30, 2023. The FDA approval is based on the results of the

The US Food and Drug Administration, FDA, approves the single tablet combination macitentan/tadalafil for pulmonary arterial hypertension, March 22, 2024 Read Post »